United States set
language
Menu Shopping cart $0 Search
Distributed product

ANDROSTENEDIONE ELISA

  • Regulatory status:RUO
  • Type:Competitive ELISA
  • Other names:A4- androstenedione, delta4 androstenedione
  • Species:Human
This product is not available in United States!
Cat. No. Size Price


DKO008 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Competitive ELISA

Applications

Serum, Plasma

Sample Requirements

25 µl/well

Shipping

Shipped on ice packs. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, all components are stable until the expiration date (see label on the box).

Calibration Range

0 - 0.1 - 0.4 - 1.2 - 4.0 - 10.0 ng/ml

Limit of Detection

0.01 ng/ml

Intra-assay (Within-Run)

n=20
CV ≤ 10.0%

Inter-assay (Run-to-Run)

n=10
CV ≤ 10.0%

Spiking Recovery

104.2 - 110.2%

Dilution Linearity

104.2 - 110.2%

Note

The kits are CE-IVD certified and intended for professional use.

Summary

Features

European Union: for in vitro diagnostic use
Rest of the world: for research use only!

The total assay time is less than 1.5 hours

Quantitative determination of androstenedione concentration in human serum or plasma

Assay format is 96 wells

Quality Control is ready to use

Calibrators are ready to use

For routine analysis

Research topic

Autoimmunity, Reproduction, Steroid hormones

Summary

Androstenedione is a steroid hormone produced in the adrenal glands and the gonads as an intermediate step in the biochemical pathway that produces the androgen testosterone and the estrogens estrone and estradiol. It is the common precursor of male and female sex hormones. Some androstenedione is also secreted into the plasma, and may be converted in peripheral tissues to testosterone and estrogens. Androstenedione has relatively weak androgenic activity, estimated at ~ 20% of testosterone. Secretion and production rates also exceed those of testosterone in women in whom significant extra- adrenal conversion of androstenedione to testosterone occurs. In premenopausal women the adrenal glands and ovaries each produce about half of the total androstendione (about 3 mg/day). After menopause androstenedione production is about halved, primarily due to the reduction of steroid secreted by the ovary. Nevertheless, androstenedione is the principal steroid produced by the postmenopausal ovary. The high serum-saliva correlation for androstenedione suggests that individual differences in serum androstenedione levels may be accurately estimated using saliva as a non-invasive alternative specimen.

Related Products Docs